The British In Vitro Diagnostics Association (BIVDA) has announced the appointment of Professor Mike Messenger as Head of Regulatory Strategy from 1 March 2024.
Professor Mike Messenger is one of the UK’s most respected figures in the regulation of medical and in vitro diagnostics. He is a visiting Professor at the University of Leeds and was formerly Head of Diagnostics at the Medicines and Healthcare products Regulatory Agency (MHRA).
During the COVID-19 pandemic, he led development of Target Product Profiles, supported government test validation groups, co-developed the CONDOR trial, and advised national and EU agencies. His work with FIND and the 100-day mission aligns closely with some of BIVDA’s core programmes.
Mike established the Leeds Centre for Personalised Medicine and Health and the National Institute for Health Research NIHR Leeds In Vitro Diagnostic Co-operative . He served for 10 years on the NICE Diagnostic Advisory Committee and is currently a member of International Standards Organisation (ISO) TC 212 working groups 1, 3 & 4 and British Standards Institute (BSI) CH 212.
Welcoming Mike, BIVDA’s Chief Executive (Interim) Helen Dent said: “The opportunity to meaningfully shape the future of medical device regulation in the UK and Europe is significant, and Mike joining us at this time enables BIVDA to re-state our position as a leading voice in regulatory affairs for IVDs. The UK’s complex and challenging regulatory landscape can be difficult for manufacturers and suppliers to navigate and Mike’s expertise and experience will also enhance our existing Regulatory team’s work to support members in delivering safe and effective products."
Mike Messenger added: “I am hugely excited to step into the role of Head of Regulatory Strategy at BIVDA. As highlighted during the pandemic, diagnostic tests are essential for global population health and as a net exporter of IVDs the sector is vital for the UK’s economic recovery. At this pivotal time for the industry, I look forward to working with BIVDA's esteemed members to support the establishment of a safer, innovative, and globally harmonised regulatory framework for IVDs. With the dual aims of improving patient health and the UK’s appeal as a destination to develop, manufacture and launch IVDs.”
